Investor Presentaiton
GAAP to non-GAAP reconciliation - Adjusted Cash Receipts
$ in millions
FY 2021
Net cash provided by operating activities (GAAP)
2,018
FY 2020
2,035
Adjustments:
Proceeds from available for sales debt securities
63
3
Distributions from equity method investees – investing
1
15
Interest paid, net
127
95
Development-stage funding payments - ongoing
7
20
Development-stage funding payments - upfront and milestones
193
6
Payments for operating and professional costs
Termination payments on derivative instruments
Distributions to non-controlling interests
Derivative collateral received, net
Adjusted Cash Receipts (non-GAAP)(1)
185
180
16
35
(480)
(544)
(45)
2,129
1,800
Amounts may not add due to rounding
ROYALTY PHARMA
(1) Refer to slide 114 for definitions. Refer to Royalty Pharma's Current Reports on Form 8-K filed with the SEC on February 15, 2022 and May 5, 2022 for additional discussion.
111View entire presentation